University College London Nov 25 2024 A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue, finds a study led by UCL researchers. The research published in Lancet Neurology , analysed data from a dozen different trials of amyloid-targeting immunotherapy - including lecanemab which has recently been approved by the UK's regulator MHRA. While brain shrinkage is usually an